Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.